You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

ESOMEPRAZOLE SODIUM Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Esomeprazole Sodium patents expire, and what generic alternatives are available?

Esomeprazole Sodium is a drug marketed by Accord Hlthcare, Deva Holding As, Eugia Pharma, Gland Pharma Ltd, Mylan, Slate Run Pharma, and Sun Pharm. and is included in seven NDAs.

The generic ingredient in ESOMEPRAZOLE SODIUM is esomeprazole sodium. There are seventy-four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the esomeprazole sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Esomeprazole Sodium

A generic version of ESOMEPRAZOLE SODIUM was approved as esomeprazole sodium by EUGIA PHARMA on August 10th, 2016.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ESOMEPRAZOLE SODIUM?
  • What are the global sales for ESOMEPRAZOLE SODIUM?
  • What is Average Wholesale Price for ESOMEPRAZOLE SODIUM?
Drug patent expirations by year for ESOMEPRAZOLE SODIUM
Recent Clinical Trials for ESOMEPRAZOLE SODIUM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Livzon Pharmaceutical Group Inc.Phase 3
Food and Drug Administration (FDA)Phase 1
BioPharma Services, IncPhase 1

See all ESOMEPRAZOLE SODIUM clinical trials

Pharmacology for ESOMEPRAZOLE SODIUM
Paragraph IV (Patent) Challenges for ESOMEPRAZOLE SODIUM
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
NEXIUM IV For Injection esomeprazole sodium 20 mg/vial and 40 mg/vial 021689 1 2009-11-23

US Patents and Regulatory Information for ESOMEPRAZOLE SODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare ESOMEPRAZOLE SODIUM esomeprazole sodium INJECTABLE;INTRAVENOUS 205379-001 Sep 25, 2015 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Mylan ESOMEPRAZOLE SODIUM esomeprazole sodium INJECTABLE;INTRAVENOUS 202686-001 May 17, 2017 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Eugia Pharma ESOMEPRAZOLE SODIUM esomeprazole sodium INJECTABLE;INTRAVENOUS 204657-002 Aug 10, 2016 AP RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Mylan ESOMEPRAZOLE SODIUM esomeprazole sodium INJECTABLE;INTRAVENOUS 202686-002 May 17, 2017 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

ESOMEPRAZOLE SODIUM Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Esomeprazole Sodium

Introduction to Esomeprazole Sodium

Esomeprazole sodium, sold under the brand name Nexium, is a proton pump inhibitor (PPI) used primarily for the management of gastroesophageal reflux disease (GERD), gastric protection, and the treatment of pathological hypersecretory conditions such as Zollinger-Ellison Syndrome[2].

Market Size and Growth

The esomeprazole sodium market has been experiencing significant growth and is anticipated to continue this trend. As of 2023, the market size was valued at USD 1,810.61 million and is projected to grow to USD 2,872.07 million by 2032, exhibiting a Compound Annual Growth Rate (CAGR) of 5.3% during the forecast period[3].

Key Drivers of Market Growth

Several factors are driving the growth of the esomeprazole sodium market:

Increasing Aging Population and Lifestyle Changes

The aging population and altering lifestyles, particularly among working individuals with hectic schedules and limited time for balanced meals, are leading to increased health complications related to digestive systems and acidity disorders. This has created a critical need for medications like esomeprazole that reduce stomach acid levels[3].

Rising Prevalence of GERD and Peptic Ulcers

The rising incidence of GERD and peptic ulcers is a major factor contributing to the market growth. In the United States, GERD is one of the most highly diagnosed digestive disorders, with a prevalence rate of 20%. Similarly, the prevalence of peptic ulcer diseases has been significant, facilitating sustainable demand for esomeprazole[3].

Technological Advancements and Healthcare Infrastructure

Technological advancements in medicine and improvements in healthcare infrastructure are also boosting market growth. The availability of latest technologies in developed and developing countries, along with growing government initiatives to promote healthcare, is fueling the demand for esomeprazole[1].

Market Segmentation

The esomeprazole sodium market is segmented based on several criteria:

Type Outlook

  • Purity: 99%
  • Purity: Above 99%
  • Others[1]

Dosage Outlook

  • Tablets
  • Capsules
  • Others[1]

Application Outlook

  • Gastro Oesophageal Reflux Disease (GERD)
  • Duodenal Ulcers
  • Others[1]

Distribution Channel Outlook

  • Hospitals & Clinical Pharmacies
  • Online
  • Over-the-Counter (OTC)[1]

Regional Outlook

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • BENELUX
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • Saudi Arabia
    • U.A.E.
    • South Africa
    • Rest of MEA[1]

Regional Market Performance

North America

North America dominates the global esomeprazole sodium market, driven by the high prevalence of GERD and peptic ulcers in the region. According to the Centre for Disease Control, around 25 million people in the United States are expected to have peptic ulcers at least once in their lifetime[3].

Asia Pacific

The Asia Pacific region is projected to be the fastest-growing region, driven by the growing elderly population and rising cases of gastroesophageal reflux. The increasing number of companies engaging in the production of esomeprazole in this region is expected to positively impact market growth[3].

Challenges and Restraints

Despite the growth, the market faces several challenges:

Adverse Effects of Long-Term Use

Long-term use of esomeprazole has been associated with adverse effects such as increased susceptibility to bacterial infections, reduced absorption of micronutrients like iron and B12, and an increased risk of developing hypomagnesemia and hypocalcemia, which may contribute to osteoporosis and bone fractures[2].

Rebound Effect

Rapid discontinuation of esomeprazole can cause a rebound effect, leading to a short-term increase in hypersecretion. This necessitates a gradual tapering of doses before discontinuing the medication[2].

Competitive Landscape

The market is highly competitive, with several key players focusing on strategies such as mergers and acquisitions, joint ventures, new product launches, agreements, and partnerships to retain their market position and expand their product base. Some of the leading companies in the market include:

  • EsteveQuímica
  • Everest Organics
  • Jubilant Pharma
  • Cemex Pharma
  • Anuja Healthcare
  • Zhejiang Davi Pharmaceutical
  • Rajasthan Antibiotics
  • Sainor Life Sciences
  • Hema Pharmaceuticals[1]

SWOT and Porter’s Five Forces Analysis

The market report includes a detailed SWOT analysis and Porter’s Five Forces analysis to provide insights into the strengths, weaknesses, opportunities, and threats of the leading players. These analyses help in understanding the competitive dynamics and the overall market structure[1].

Impact of COVID-19

The COVID-19 pandemic has significantly impacted the pharmaceutical and healthcare sector, including the esomeprazole sodium market. The pandemic has led to increased investments in research and development, improvements in healthcare infrastructure, and a growing need for early diagnosis and precision medicine. These factors have contributed to the market growth during the pandemic[1].

Key Takeaways

  • The esomeprazole sodium market is expected to grow significantly, driven by the increasing aging population, lifestyle changes, and rising prevalence of GERD and peptic ulcers.
  • North America dominates the market, while the Asia Pacific region is expected to be the fastest-growing.
  • The market faces challenges such as adverse effects of long-term use and rebound effects upon discontinuation.
  • Key players are focusing on strategic developments to maintain their market position.

FAQs

1. What is the primary use of esomeprazole sodium? Esomeprazole sodium is primarily used for the management of gastroesophageal reflux disease (GERD), gastric protection, and the treatment of pathological hypersecretory conditions such as Zollinger-Ellison Syndrome[2].

2. What is the projected market size of esomeprazole sodium by 2032? The market is anticipated to grow to USD 2,872.07 million by 2032, exhibiting a CAGR of 5.3% during the forecast period[3].

3. Which region dominates the global esomeprazole sodium market? North America dominates the global esomeprazole sodium market, driven by the high prevalence of GERD and peptic ulcers in the region[3].

4. What are the major challenges faced by the esomeprazole sodium market? The market faces challenges such as adverse effects of long-term use, rebound effects upon discontinuation, and the need for careful dose tapering[2].

5. Who are some of the key players in the esomeprazole sodium market? Key players include EsteveQuímica, Everest Organics, Jubilant Pharma, Cemex Pharma, Anuja Healthcare, and others[1].

Cited Sources

  1. Reports and Data, "Esomeprazole Sodium Market Size, Share, Industry Growth, Trend, Business Opportunities, Challenges, Drivers, and Restraint Research Report by 2027".
  2. DrugBank Online, "Esomeprazole sodium".
  3. Polaris Market Research, "Esomeprazole Market Size, Share, Global Analysis Report 2024-2032".

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.